Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)
NCT ID: NCT00942864
Last Updated: 2016-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
40 participants
INTERVENTIONAL
2008-12-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
NCT02944227
Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO
NCT02091505
Ranibizumab Treatment for Retinal Vein Occlusion
NCT01968616
Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion
NCT02144662
Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion
NCT01028248
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ranibizumab
ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with macular edema due to RVO (confirmed by fundus photography, fluorescein angiography, OCT)
* Male and female aged from 18 to 70
* Baseline best-corrected visual acuity (BCVA) in the study eye was from 20/400 to 20/30 using ETDRS chart
Exclusion Criteria
* Ocular inflammation
* Intraocular surgery ≤ 1 month before day 0
* Uncontrolled glaucoma
* Prior treatments with laser photocoagulation or other intervention for macular edema due to BRVO
* Patients aged under 18 or over 71
* Female patient in pregnancy or breast feeding
* Not suitable to regular follow up
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Korea Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seung-Young Yu
Role: PRINCIPAL_INVESTIGATOR
Dept. ophthalmology, Kyunghee medical center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept. of ophthalmology, Kyung Hee University Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRFB002AKR07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.